Literature DB >> 26239629

Good Intentions, Unintended Consequences, and Unrealized Benefits.

John D FitzGerald1.   

Abstract

Mesh：

Substances：

Year:  2015        PMID： 26239629      PMCID： PMC4617926          DOI： 10.1007/s11606-015-3458-4

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN： 0884-8734            Impact factor:   5.128


× No keyword cloud information.
  5 in total

1.  Incentives for drug development—the curious case of colchicine.

Authors:  Janet Woodcock; Sarah Okada
Journal:  N Engl J Med       Date:  2010-10-07       Impact factor: 91.245

2.  High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study.

Authors:  Robert A Terkeltaub; Daniel E Furst; Katherine Bennett; Karin A Kook; R S Crockett; Matthew W Davis
Journal:  Arthritis Rheum       Date:  2010-04

3.  Reductions in Use of Colchicine after FDA Enforcement of Market Exclusivity in a Commercially Insured Population.

Authors:  Aaron S Kesselheim; Jessica M Franklin; Seoyoung C Kim; John D Seeger; Daniel H Solomon
Journal:  J Gen Intern Med       Date:  2015-04-09       Impact factor: 5.128

4.  The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts.

Authors: 
Journal:  Blood       Date:  2013-04-25       Impact factor: 22.113

Review 5.  A concise history of gout and hyperuricemia and their treatment.

Authors:  George Nuki; Peter A Simkin
Journal:  Arthritis Res Ther       Date:  2006-04-12       Impact factor: 5.156
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.